Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears® Supplement for Dry Eyes, Blink® Triple...
Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, All Primary Endpoints AchievedBausch + Lomb Corporation (TSX:...
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better...
RBC Capital analyst Douglas Miehm maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and raises the price target from...
Citigroup analyst Joanne Wuensch maintains Bausch & Lomb (TSX:BLCO) with a Buy and raises the price target from C$22 to ...
Acquisition Represents Significant Opportunity for Growth in Prescription Dry Eye Segment Bausch + Lomb Corporation (TSX:BLCO)...
RBC Capital analyst Douglas Miehm reiterates Bausch & Lomb (NYSE:BLCO) with a Outperform and maintains $20 price target.
Bausch & Lomb (TSX:BLCO) reported quarterly earnings of $0.10 per share. This is a 58.33 percent decrease over earnings of ...
RBC Capital analyst Douglas Miehm reiterates Bausch & Lomb (NYSE:BLCO) with a Outperform and maintains $20 price target.
